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BACKGROUND: There is a need for simple imaging parameters capable of predicting therapeutic outcome.
METHODS: This retrospective study analysed 50 patients with locally advanced carcinoma of the cervix who underwent dynamic
contrast-enhanced MRI before receiving potentially curative radiotherapy. The proportion of enhancing pixels (EF) in the
whole-tumour volume post-contrast agent injection was calculated and assessed in relation to disease-free survival (DFS).
RESULTS: Tumours with high EF had a significantly poorer probability of DFS than those with low EF (P¼0.011).
INTERPRETATION: EF is a simple imaging biomarker that should be studied further in a multi-centre setting.
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Carcinoma of the cervix is the second most common cancer in
women and a significant cause of mortality worldwide (Monk et al,
2009). Outcome of patients with locally advanced disease has
improved in recent years with the adoption of concurrent
chemoradiotherapy (Green et al, 2001). However, the overall
5-year survival rate is still only around 60% and the use of
concurrent chemotherapy may increase the risk of late toxicity
(Spensley et al, 2009). Consequently, there is a need to predict,
before treatment, those patients likely to respond to radiotherapy
alone and those who might benefit from combination therapy
and/or the addition of novel targeted therapeutic agents.
There is interest in developing imaging biomarkers that predict
cancer treatment outcome. Dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) can be used to estimate micro-
vascular parameters such as tissue perfusion and capillary
permeability. Some of the parameters have been shown to correlate
with histological measurements of angiogenesis (Mayr et al, 1996;
Hawighorst et al, 1999) and tumour oxygenation (Cooper et al,
2000) and have had some success in predicting treatment
outcome (Loncaster et al, 2002). Although tracer kinetic analysis
of DCE-MRI data results in the estimation of physiologically
relevant parameters, the requirement for high-temporal resolution
data – enabling an arterial input function (Parker et al, 2006) to be
obtained – and pre-contrast T1 measurements make DCE-MRI
studies difficult to implement. There is interest, therefore, in
developing simple imaging biomarkers of tumour physiology.
Enhancing fraction (EF) assessed using DCE-MRI or CT has
been presented as a simple method of assessing whole-tumour
vascularity. Enhancing fraction is the proportion of tissue within a
tumour that enhances and has been shown to predict treatment
outcome in ovarian (O’Connor et al, 2007) and other solid
tumours (Mullamitha et al, 2007) and has been used to assess
treatment efficacy of an anti-angiogenic agent (Jayson et al, 2005).
The aim of this study was to investigate whether EF measured with
DCE-MRI was able to predict treatment outcome in patients with
carcinoma of the cervix.
MATERIALS AND METHODS
Patients
Approval from a local ethics committee was obtained and all
patients gave informed consent. Fifty patients with locally
advanced carcinoma of the cervix underwent pre-treatment
MRI scans. Patients subsequently received 40–45Gy external
beam radiotherapy (EBRT) to the pelvis – 20 fractions over
28 days – followed by low dose rate intracavitary brachytherapy
(22.5 32.5Gy). Disease-free survival (DFS) was calculated from
the date of start of radiotherapy to date of disease recurrence or
latest follow-up date where no recurrence occurred.
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sMR protocol
MRI scans were performed on a 1T Siemens Magnetom Impact
(Siemens Healthcare, Frimley, UK). Staging scans were carried out
as previously described (Cooper et al, 2000; Loncaster et al, 2002).
Dynamic scans used a sagittal 2D T1-weighted FLASH sequence
(TR/TE¼130/6.5ms, FOV¼290 290 5mm, matrix¼256 256,
NSA¼1, a¼701) with a temporal resolution of 25s. One sequence
of nine contiguous slices covering the whole-tumour volume was
obtained before and seven after injection of 0.1mmolkg
 1 body
weight Gd-DTPA.
Data analysis
Regions of interest (ROIs) encompassing the whole tumour
were defined by an experienced radiologist on the pre-contrast
T2-weighted images. Regions of interest were transferred to the
dynamic data series. Data analysis was carried out using IDL
(Research Systems Inc., Boulder, CO, USA). Tumour volumes were
calculated by multiplying the number of pixels in the ROI by the
voxel dimensions. A threshold for enhancing pixels was defined as
a signal change greater than three times the standard deviation
(s.d.) of signal values over the whole-tumour volume calculated in
the pre-contrast image. The number of pixels that exceeded this
threshold at 25 and 50s post-contrast agent injection was
calculated and divided by the total number of pixels in the tumour
ROI to obtain EF at 25 and 50s, respectively.
Pearson correlations between tumour volume and EF at 25 and
50s were investigated using SPSS (SPSS Inc., Chicago, IL, USA).
Spearman correlations between tumour stage and tumour volume,
EF at 25 and 50s were assessed. Tumours were stratified into two
groups – those with tumour volume, stage and EF above or below
the median. Kaplan–Meier curves were produced and a log-rank
test performed to investigate significant differences in DFS. A
significance level of 0.05 with a Bonferroni correction for multiple
comparisons was used. A Fisher’s exact test was used to assess
differences in EF at 25s in tumours of different size, stage, nodal
status and age of the patient.
RESULTS
Patient details are shown in Table 1. The median age of the 50
women was 63 years (range 29–82 years). The median tumour
volume was 49.9cm
3 (range 6.8–184.2cm
3); 46 tumours were
squamous cell carcinomas, 3 were adenosquamous cell carcinomas
and 1 was adenocarcinoma; 26 and 24 patients had negative
and positive nodal status, respectively. The median follow-up time
in surviving patients was 105 months (range 86–128 months).
A total of 32 patients had recurrence of their disease at the time of
writing – 8 patients had local recurrence only, 9 patients had
distant recurrence only, 13 had local and distant recurrence and 2
had residual disease after treatment.
Figure 1 shows the distribution of enhancing pixels for EF
calculated at 25 and 50s, respectively, for one patient. Enhancing
fraction at 25s post-contrast was higher in larger tumours
(Po0.01). The results of correlations are shown in Table 2. There
was a weak positive correlation between tumour volume and EF at
25s (r¼0.37, Po0.01). There were no associations between EF at
50s post-contrast and any clinicopathological parameter.
Figure 2 shows the Kaplan–Meier curves for patients stratified
by median EF at 25s (28.4%). There was a significant difference
between DFS in patients with high and low tumour EF at 25s
(P¼0.011). Enhancing fraction calculated at 50s was not
associated with DFS. In this cohort of patients neither baseline
tumour volume (P¼0.88) nor disease stage (P¼0.09) had
prognostic significance.
DISCUSSION
A total of 50 patients with carcinoma of the cervix underwent DCE-
MRI scans before receiving EBRT. We calculated EF at two time
points to examine the prognostic significance of EF in this patient
group. Patients with tumours with an EF at 25s greater than the
median had a significantly poorer DFS than those with low EF,
concurring with a similar study in ovarian cancer (O’Connor et al,
2007). This finding is consistent with high EF reflecting more
vascular and angiogenic tumours that are more likely to recur than
those with low EF. The observation is consistent with work
Table 1 Summary of the distribution of patients as stratified by median
EF at 25s (28.4%)
Parameter n
Low
EF at 25s (n)
High
EF at 25s (n) P-value
a
Stage 0.047
I1 1 0
II 25 13 12
III 23 10 13
IVA 1 1 0
Tumour volume o0.01
b
Less than median 25 17 8
Greater than median 25 8 17
Age (years) 0.157
p62 25 11 14
462 25 14 11
Nodal status 0.018
Negative 26 17 9
Positive 24 8 16
aAssessed by Fisher’s exact test.
bSignificant at the 0.05 level with Bonferonni
correction applied for multiple comparisons.
Figure 1 EF in a cervix tumour (squamous cell carcinoma, stage IIIB) at
25 (36.5%) and 50s (95.9%), respectively. The pre-treatment EF at 25s was
greater than the median and the patient subsequently developed local
recurrence and metastases and died from their disease 17 months after
diagnosis.
Table 2 Results of correlations between parameters
EF at
25s
EF
at 50s
Tumour
volume
Tumour
stage
EF at 25s — 0.596
a 0.374
a  0.025
EF at 50s 0.596
a — 0.296  0.011
Tumour volume 0.374
a 0.296 — 0.148
Tumour stage  0.025  0.011 0.148 —
Pearson correlations are presented in all cases except for correlations between
parameters with tumour stage that used a Spearman’s test.
aSignificant at 0.05 level
with Bonferroni correction applied for multiple comparisons.
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s(Hawighorst et al, 1998) in which high kep – a rate constant
describing the transfer of contrast agent between the vascular and
the interstitial space – was indicative of a poor prognosis.
Other studies in cervical cancer have shown that high amplitude
of enhancement is related to improved patient survival. Previous
work involving a subset of this patient group (Loncaster et al,
2002) showed that high A
H – a parameter dependent on the size of
the interstitial space (Hoffman et al, 1995) – was associated
with improved patient survival. Similarly, Mayr et al (1996)
showed that high relative signal intensity (rSI) – the ratio of post-
to pre-contrast signal – resulted in improved prognosis. These
results suggest that EF measured early in the dynamic time series
provides different physiological information from A
H and rSI. We
postulate that EF at 25s is likely to relate to tissue perfusion
whereas A
H and rSI are associated with the size of the interstitial
space. A low EF may also be consistent with a large hypoxic
fraction; however, further work is needed to characterise the
precise relationship, if any, between EF and hypoxic fraction.
Recent work (Zahra et al, 2009) showed a weak correlation
between kep and tumour regression measured at 5 weeks after
radiotherapy, with high enhancement being associated with better
tumour regression; however, the results of long-term follow-up
were not presented.
This study involved the retrospective analysis of data collected
between July 1997 and August 2000. Few dynamic data points were
acquired and the 25-s temporal resolution precluded accurate
tracer kinetic analysis. The MRI signal threshold above
which pixels are said to have enhanced was calculated using the
s.d. of the baseline signal in the whole-tumour ROI due to the
lack of multiple baseline (pre-contrast) data points. Despite
this limitation, we showed a significant relationship between EF
and patient outcome. This finding agrees with other studies
(Mullamitha et al, 2007; O’Connor et al, 2007) where the precise
method of defining enhancement varied, showing that only a few
dynamic data points and an accurate assessment of baseline
tumour volume are required for calculation of EF. Although EF is
simple to calculate when compared with tracer kinetic analysis,
precise definitions of enhancement will vary with the MR protocol
being used, magnet strength, contrast agent dose and rate of
administration. These factors may affect the precision of the
measurement but EF at 25s should still reflect tissue perfusion, as
hypothesised, and be capable of predicting DFS. Studies with more
baseline signal data have used statistical techniques (O’Connor
et al, 2009) to define enhancing pixels. Further work in larger
prospective studies is therefore required to establish how best to
define a threshold; however, our results add weight to the
development of EF as an imaging biomarker applicable to routine
clinical use.
The patients included in this study were treated up to 10 years
ago, when radiotherapy alone was commonly prescribed as
treatment of choice. Current best practice recommends concurrent
chemoradiotherapy for patients with carcinoma of the cervix, so it
is important to test whether EF has the same prognostic potential
in this patient group. However, patients with locally advanced
disease still receive radiotherapy alone if they have inadequate
renal function for chemotherapy.
In conclusion, the results of this retrospective study suggest
that EF measured using DCE-MRI is capable of predicting DFS
in patients with carcinoma of the cervix. High EF was associated
with poor prognosis. Enhancing fraction is a simple imaging
biomarker and does not rely on sophisticated MRI techniques or
data analysis. Confirmation in further datasets should be carried
out to validate EF as a biomarker of prognosis in locally advanced
carcinoma of the cervix.
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Figure 2 Kaplan–Meier curves showing the relationship between
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stratified by the median EF at 25s that was 28.4%. Numbers of patients in
each arm and statistical significance are indicated.
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